Leading the Way in Life Science Technologies

GEN Exclusives

More »

Roundtable Discussions

More »
Sep 1, 2009 (Vol. 29, No. 15)

Cellular Imaging and Analysis Roundtable

Past, Present, and Future of Enabling Technology in Academia and Industry

  • Click Image To Enlarge +
    Kelvin Lam, Ph.D.

    GEN  Are there bottlenecks, and if so, where are they?

    Lam: There are three bottlenecks: image acquisition, software to analyze the image data, and information management. These are the areas we need to improve upon, rather than just the hardware.

    von Leoprechting: We are collaborating with the open-source networks to help break some of the bottlenecks in image analysis and storage. The point is not just managing and analyzing the data, but also making it more accessible to users. This is also where we see the difference between some of the pharma labs, especially in assay development, and academic labs.

    In academia you often have many highly experienced experts who can run complex data-mining and data-analysis programs. But  in a drug discovery therapeutic group, such expertise is often not available for assay development, as this knowledge mainly resides in the screening labs. So you would need to develop two-tiered software packages—one for the experts and one to allow new users to set up assays easy and fast.

    Evans: I definitely believe that information management has been a key aspect of being able to scale high-content screening. One of the problems that we’ve been facing for the last few years is how to actually take all that information and build knowledge, because that’s what you ultimately want. You want to be able to make informed decisions on which drugs to develop or which targets to follow up on.

    A major part of the pipeline that is missing is a modeling environment where new information can be piped in as it is being generated and models refined.  



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »